Evidence map›Paper›PMID 41201142›Full record

ArticleSmall (Weinheim an der Bergstrasse, Germany)2025

Designing Programmable Peptide Nucleic Acid-based Nanovaccines for Anticancer Immune Activation.

Yanyu Huang, Cuiqing Huang, Sakshi Pandita, Chon Man Ieong, Yongheng Wang, David Wang, Jifeng Chen, Victorio Jauregui-Matos, Alessandra Maria Arabelle Beelen, Ya-Ping Shiau and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Small (Weinheim an der Bergstrasse, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Yanyu HuangDepartment of Biochemistry and Molecular Medicine, University of California, Davis, Sacramento, CA, 95817, USA.ORCID 0000-0002-4134-944X
Cuiqing HuangGuangdong Women and Children Hospital, Guangzhou, 511442, China.
Sakshi PanditaDepartment of Biochemistry and Molecular Medicine, University of California, Davis, Sacramento, CA, 95817, USA.
Chon Man IeongRadiology Department, Centro Hospitalar Conde de São Januário, Estrada do Visconde de S. Januário, Macau, Macao SAR, 999078, China.
Yongheng WangDepartment of Biochemistry and Molecular Medicine, University of California, Davis, Sacramento, CA, 95817, USA.
David WangDepartment of Biomedical Engineering, University of California, Davis, Sacramento, CA, 95817, USA.
Jifeng ChenThe Guangzhou Key Laboratory of Molecular and Functional Imaging for Clinical Translation, The First Affiliated Hospital of Jinan University, Guangzhou, 510632, China.
Victorio Jauregui-MatosDepartment of Chemistry, University of California, Davis, CA, 95616, USA.
Alessandra Maria Arabelle BeelenDepartment of Chemistry, University of California, Davis, CA, 95616, USA.
Ya-Ping ShiauDepartment of Biochemistry and Molecular Medicine, University of California, Davis, Sacramento, CA, 95817, USA.
Shiqi TangDepartment of Biochemistry and Molecular Medicine, University of California, Davis, Sacramento, CA, 95817, USA.
Junwei ZhaoDepartment of Biochemistry and Molecular Medicine, University of California, Davis, Sacramento, CA, 95817, USA.
Qiufang ZongDepartment of Biochemistry and Molecular Medicine, University of California, Davis, Sacramento, CA, 95817, USA.
Menghuan TangDepartment of Biochemistry and Molecular Medicine, University of California, Davis, Sacramento, CA, 95817, USA.
Zhaoqing CongDepartment of Biochemistry and Molecular Medicine, University of California, Davis, Sacramento, CA, 95817, USA.
Yuanpei LiDepartment of Biochemistry and Molecular Medicine, University of California, Davis, Sacramento, CA, 95817, USA.
Peter A BealDepartment of Chemistry, University of California, Davis, CA, 95616, USA.
Sheila S DavidDepartment of Chemistry, University of California, Davis, CA, 95616, USA.
Aijun WangDepartment of Biomedical Engineering, University of California, Davis, Sacramento, CA, 95817, USA.
Duo WangCenter of Interventional Radiology & Vascular Surgery, Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing, 210009, China.
Zeyu XiaoThe Guangzhou Key Laboratory of Molecular and Functional Imaging for Clinical Translation, The First Affiliated Hospital of Jinan University, Guangzhou, 510632, China.
Kit S LamDepartment of Biochemistry and Molecular Medicine, University of California, Davis, Sacramento, CA, 95817, USA.ORCID 0000-0002-3076-6969

Funding

Staff InvestigatorsP30CA093373 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI KC KENT LLOYD · 2002 to 2026
$84.9M
HER2-targeting transformable nanotherapeutic platform against HER2+ cancersR01CA247685 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI LAM, KIT S · 2020 to 2024
$3.1M
Elucidating Mechanisms of Recognition and Excision of Damaged Bases by NEIL glycosylasesR01GM143557 · NIGMS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI DAVID, SHEILA SUE · 2021 to 2024
$1.2M
China Postdoctoral Science Foundation 2024M750452National Natural Science Foundation of China 82271943National Natural Science Foundation of China 82402408NCI NIH HHS P30 CA093373NCI NIH HHS R01 CA247685NIGMS NIH HHS R01 GM143557NIH grant R01CA247685
6 · The paper itself

Abstract

Targeted delivery of antigens and adjuvants to the immune cells without eliciting uncontrolled inflammation is a major challenge in cancer vaccine development. Here, a highly versatile and programmable peptide nucleic acid (PNA)-based vaccine nanoplatform (PVN) is reported to elicit a robust anti-tumor immune response against B16-OVA syngeneic melanoma model. The PVN is built on an 11-mer PNA scaffold, enabling efficient "one-pot" loading of a PNA-modified ovalbumin antigenic peptide (SIINFEKL), CpG adjuvant, and a PNA-derivatized LLP2A ligand (an immune cell and melanoma cell targeting ligand). Super-resolution fluorescence imaging reveals the spatial arrangement of OVA

Indexed as

Cancer VaccinesNanoparticlesPeptide Nucleic AcidsAnimalsCell Line, TumorMelanoma, ExperimentalMiceMice, Inbred C57BLNanovaccinesCancer VaccinesNanovaccinesPeptide Nucleic Acidscancer immunotherapydendritic cellsmelanomananovaccinepeptide nucleic acid

Identifiers

PMID41201142
PMCPMC12723328

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.